Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

NCT01225562 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

21379

Enrollment

INDUSTRY

Sponsor class

Conditions

Myocardial Infarction
Cardiovascular Death
Atherothrombosis
Stroke

Interventions

DRUG: Ticagrelor 90 mg
DRUG: Ticagrelor 60 mg
DRUG: Ticagrelor Placebo

Sponsor

AstraZeneca